PubMed

FDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program.

PMID: 40587167 · 2025-08-01

K, u, s, h, a, l, , T, , K, a, d, a, k, i, a, ;, , S, a, n, k, e, t, , S, , D, h, r, u, v, a, ;, , J, o, s, e, p, h, , S, , R, o, s, s, ;, , J, a, m, e, s, , F, , B, u, r, k, e, ;, , J, a, m, e, s, , L, , J, o, h, n, s, t, o, n, ;, , R, e, s, h, m, a, , R, a, m, a, c, h, a, n, d, r, a, n, ;, , H, a, r, l, a, n, , M, , K, r, u, m, h, o, l, z, ;, , V, i, n, a, y, , K, , R, a, t, h, i

ЖурналJAMA internal medicine

Год2025-08-01

PMID40587167

Аннотация

Congress established the US Food and Drug Administration (FDA) Breakthrough Devices Program (BDP) in 2016 to promote technological innovation and facilitate patient access. However, the clinical and regulatory characteristics of FDA-designated breakthrough devices have not been assessed. To characterize technological novelty, FDA review times, and premarket and postmarket evidence requirements for therapeutic breakthrough-designated devices. This cross-sectional study analyzed publicly available

Официальный источник

Открыть в PubMed →

Данные получены из PubMed / NCBI. Полный текст и наиболее актуальную информацию всегда смотрите в официальной записи.